The potential cardiovascular benefits of aspirin are outweighed by the risk of nontrivial bleeding in people without cardiovascular disease (CVD), a meta-analysis has shown. The researchers analysed nine randomised placebo-controlled trials reporting on cardiovascular disease, non-vascular outcomes or death.